New therapy combined with immunology, molecular biology and medical technology for patients with peritoneal carcinosis

本研究的重点是结合免疫学、分子生物学和医学技术开发新的治疗策略，以治疗预后不良的腹膜癌患者。本研究期间获得的数据如下：(1)为了开发新的治疗方法和阐明腹膜癌的生物学特性，利用手术切除标本中获得的各种类型的细胞，开发了腹膜、结缔组织和淋巴结等人工组织。(2)利用这些开发的人工组织，新开发了类似于人硬痂型胃癌组织的人工癌组织。此外，一种可能的新的治疗策略，即干扰素- γ治疗的胃硬膜癌，是利用这种人造癌组织开发的。(3)采用人工腹膜建立新型腹膜癌模型。在此基础上，开发了一种新的治疗腹膜癌的免疫疗法，称为“免疫监视系统重建疗法”。(4)“基于外周血干细胞移植和树突状细胞（DC）疫苗对胸膜和腹膜癌患者免疫监视系统重建治疗”的I期研究（19例）基本完成。最初计划的实验没有完全进行。然而，我们新开发了几种人工组织，包括腹膜、结缔组织、淋巴结和癌组织，并建立了新的治疗策略，称为“干扰素- γ治疗”和“免疫监视系统重建治疗”。特别是开始了“腹膜癌患者免疫监测系统重建治疗”的临床应用。

This study was focused on the development of new therapeutic strategy combined with immunology, molecular biology, and medical technology for poor prognostic patients with peritoneal carcinosis. Data obtained for duration of this study are as follows :(1) In order to develop new therapy and elucidate biological characteristics of peritoneal carcinosis, artificial tissues such as peritoneum, connective tissue, and lymphnodes were developed using various types of cells obtained from surgically resected specimens.(2) Using these developed artificial tissues, artificial carcinoma tissue similar to human scirrhous type-gastric carcinoma tissue was newly developed. In addition, a possible new therapeutic strategy for scirrhous carcinoma of the stomach, i.e., interferon-gamma therapy, was developed using this artificial carcinoma tissue.(3) New model of peritoneal carcinosis was developed using artificial peritoneum. New immunotherapy which is called "reconstruction therapy of immune surveillance system", for peritoneal carcinosis was developed using this new model.(4) Phase I study (19 patients) of "reconstruction therapy of immune surveillance system based on peripheral blood stem cell transplantation and dendritic cell (DC) vaccine for patients with pleural and peritoneal carcinosis" was almost completed.Experiments planned originally were not completely carried out. However, we newly developed several artificial tissues, including peritoneum, connective tissue, lymphnode, and carcinoma tissue, and we established new therapeutic strategies which are called "interferon-gamma therapy" and "reconstruction therapy of immune surveillance system". Especially, clinical application of "reconstruction therapy of immune surveillance system for patients with peritoneal carcinosis" started.